



Ifw

LA0091 US - NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sammy G. Duncan, Jr., Ph.D.
Type or print name

Signature

October 14, 2005
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**IN RE APPLICATION OF
LAWRENCE HAMANN, ET AL**

**ART UNIT: 1624
EXAMINER: BALASUBRAMANIAN,
VENKATARAMAN**

**APPLICATION NO: 10/712456
FILED: 11/13/2003
FOR: OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF
ANDROGEN RECEPTOR FUNCTION**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

COMMUNICATION

In response to the Restriction Requirement mailed September 28, 2005, in connection with the above-identified application. Applicants request entry of the following remarks

REMARKS


Responsive to the Restriction Requirement dated September 28, 2005, Applicants elect, with traverse, Group I "drawn to compound of formula I, wherein $n=1$, namely pyrrolidine, classified in class 546, subclass 567, 570, class 514, subclasses 423, 428, and other classes and subclasses depending upon the choice of G and other heterocyclic cores embraced in the claims." (September 28, 2005 Restriction Requirement, page 2).

Applicants respectfully traverse the requirement for an Election on the grounds that the reasons stated by the Examiner do not support his contention that separate searches would be required during the examination of the present application. One of skill in the art at the time of the application would have readily discerned that when variable n is either 1 or 2 the claims of the present application cover small, heterocyclic compounds useful as therapeutics. Applicants do not

believe that a serious burden would be imposed upon the Examiner to search the Applicants' claimed genus of compounds.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Sammy G. Duncan, Jr. Ph.D.
Attorney for Applicant
Reg. No. 46675
Phone: 609-252-6270
Date: October 14, 2005